文献速递药物相互作用抗栓抗凝管理

贯叶金丝桃对利伐沙班药代动力学和药效学的影响

Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans.
PubMed 文献 · Br J Clin Pharmacol · 2020-10-25

本研究在12名健康志愿者中探讨贯叶金丝桃提取物对利伐沙班药代动力学和药效学的影响,采用开放标签、非随机、序贯治疗相互作用研究。结果显示贯叶金丝桃提取物诱导CYP3A4和P-gp,使利伐沙班AUC和Cmax几何均值比分别降至0.76和0.86,抗Xa活性AUC比降至0.80。结论认为虽不构成禁忌或系统剂量调整,但应避免联用或考虑实验室监测。

要点

  • 贯叶金丝桃提取物使利伐沙班AUC降至0.76倍,Cmax降至0.86倍。
  • 抗Xa活性抑制相应降低,AUC比为0.80。
  • 含贯叶金丝桃素提取物与利伐沙班联用应避免或监测。

核心结论

  • CYP3A4/P-gp诱导型贯叶金丝桃提取物使利伐沙班暴露量降低,药效学效应成比例下降。
  • 数据不支持禁忌联用或系统调整利伐沙班剂量,但建议避免联用或进行实验室监测。

研究设计与样本

  • 开放标签、非随机、序贯治疗相互作用研究,纳入12名健康志愿者。
  • 先用低剂量咪达唑仑和非索非那定进行CYP3A4和P-gp表型分析,再给予单次口服20 mg利伐沙班,测定给药前至给药后48小时的利伐沙班血浆浓度和活化凝血因子X抑制率。
  • 经2周贯叶金丝桃提取物治疗后重复上述程序。

主要发现

  • 贯叶金丝桃提取物诱导后/诱导前利伐沙班AUC几何均值比为0.76(90% CI 0.70, 0.82),Cmax几何均值比为0.86(90% CI 0.76, 0.97)。
  • 抗Xa活性抑制效应-时间曲线下面积几何均值比为0.80(90% CI 0.71, 0.89)。
  • 表型分析证实贯叶金丝桃提取物显著诱导CYP3A4和P-gp活性。

关键数值与推荐

  • 利伐沙班AUC几何均值比0.76(90% CI 0.70, 0.82)。
  • 利伐沙班Cmax几何均值比0.86(90% CI 0.76, 0.97)。
  • 抗Xa活性效应-时间曲线下面积几何均值比0.80(90% CI 0.71, 0.89)。

临床怎么用

  • 服用含贯叶金丝桃素贯叶金丝桃提取物的患者应避免联用利伐沙班或进行实验室监测。
  • 联用时无需系统调整利伐沙班剂量,但需警惕暴露量和抗Xa活性下降。

局限性

  • 研究为开放标签、非随机设计,样本量较小(12名健康志愿者)。
  • 单次给药研究,未评估长期联用的临床结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the influence of a cytochrome P450 CYP3A4 and efflux transporter P-glycoprotein (P-gp) inducing Hypericum perforatum extract on the pharmacokinetics and pharmacodynamics of rivaroxaban. METHODS: Open-label, nonrandomized, sequential treatment interaction study. Following CYP3A4 and P-gp phenotyping using low-dose midazolam and fexofenadine, 12 healthy volunteers received a single oral dose of 20 mg rivaroxaban and rivaroxaban plasma concentrations and inhibition of the activated coagulation factor X (factor Xa) activity were measured prior to and up to 48 h postdosing. The procedures were repeated after 2 weeks' treatment with the H. perforatum extract. RESULTS: The geometric mean ratios for the area under the concentration-time curve and Cmax of rivaroxaban after/before induction with the H. perforatum extract were 0.76 (90% confidence interval [CI] 0.70, 0.82) and 0.86 (90% CI 0.76, 0.97), respectively. Inhibition of factor Xa activity was reduced with a geometric mean area under the effect-time curve ratio after/before induction of 0.80 (90% CI 0.71, 0.89). No clinically significant differences were found regarding Tmax (median 1.5 vs 1 h, P = .26) and terminal elimination half-life (mean 10.6 vs 10.8 h, P = .93) of rivaroxaban. The H. perforatum extract significantly induced CYP3A4 and P-gp activity, as evidenced by phenotyping. CONCLUSION: The CYP3A4/P-gp inducing H. perforatum extract caused a decrease of rivaroxaban exposure with a proportional decrease of the pharmacodynamic effect. Although the data do not justify a contraindication for the combination or a systematic adjustment of rivaroxaban dosage, avoidance of the combination or laboratory monitoring should be considered in patients taking hyperforin-containing H. perforatum extracts with rivaroxaban.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Scholz I, Liakoni E, Hammann F, et al. Effects of Hypericum perforatum (St John's wort) on the pharmacokinetics and pharmacodynamics of rivaroxaban in humans. Br J Clin Pharmacol. 2020. PMID: 32959922. doi:10.1111/bcp.14553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。